Andere talen Genenta Science S.p.A.

Aandelen

GNTA

US36870W1009

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,916 ^USD	+30,52%		+12,84%	-20,90%

08/04	Genenta Science S.P.A. kondigt ontslag van bestuursleden aan	CI
29/03	Genenta Science S.p.A. rapporteert resultaten voor het volledige jaar eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Genenta Science S.P.A. Announces Resignation of Board Members	08/04
Genenta Science S p A : NOTICE OF CALL OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING - Form 6-K	02/04
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors	08/02
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors	08/02
Genenta Science Demonstrated Reprogramming of the Tumor Microenvironment in Gbm Patients, Paving the Way for Innovative Treatments of Solid Tumors	08/02
Sandoz kauft Medikament Cimerli für 170 Millionen US-Dollar von Coherus	22/01
Sandoz to Acquire Cimerli Business from Coherus for $170 Million	22/01
Genenta Science S p A : Consolidated Statements of Operations and Comprehensive Loss - Form 6-K	20-10-23
Genenta Science S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2023	20-10-23
Genenta to Present at Upcoming Scientific and Investor Conferences	06-09-23
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	28-07-23
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	28-07-23
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	28-07-23
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma	29-06-23
Health Care Stocks Support American Depositary Receipts of European Equities	16-06-23
Genenta to Provide Update on Lead Product Temferon™	16-05-23
Genenta Science S p A : NOTICE OF CALL OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING - Form 6-K	10-05-23
Genenta Science S p A : Effectiveness of the Amended and Restated OSR License Agreement - Form 6-K	01-05-23
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing	26-04-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Genenta Science S.p.A.

Aandelen

GNTA

US36870W1009

Andere talen

Filters